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Endoglin (ENG) is a coreceptor of the transforming growth factor-β
(TGFβ) family signaling complex, which is highly expressed on en-
dothelial cells and plays a key role in angiogenesis. Its extracellular
domain can be cleaved and released into the circulation as soluble
ENG (sENG). High circulating levels of sENG contribute to the path-
ogenesis of preeclampsia (PE). Circulating bone morphogenetic
protein 9 (BMP9), a vascular quiescence and endothelial-protective
factor, binds sENG with high affinity, but how sENG participates in
BMP9 signaling complexes is not fully resolved. sENG was thought
to be a ligand trap for BMP9, preventing type II receptor binding
and BMP9 signaling. Here we show that, despite cell-surface ENG
being a dimer linked by disulfide bonds, sENG purified from human
placenta and plasma from PE patients is primarily in a monomeric
form. Incubating monomeric sENG with the circulating form of
BMP9 (prodomain-bound form) in solution leads to the release of
the prodomain and formation of a sENG:BMP9 complex. Further-
more, we demonstrate that binding of sENG to BMP9 does not in-
hibit BMP9 signaling. Indeed, the sENG:BMP9 complex signals with
comparable potency and specificity to BMP9 on human primary en-
dothelial cells. The full signaling activity of the sENG:BMP9 complex
required transmembrane ENG. This study confirms that rather than
being an inhibitory ligand trap, increased circulating sENG might
preferentially direct BMP9 signaling via cell-surface ENG at the en-
dothelium. This is important for understanding the role of sENG in
the pathobiology of PE and other cardiovascular diseases.
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Endoglin (ENG) is a homodimeric transmembrane glycopro-tein that is strongly expressed on endothelial cells (ECs) (1).
Loss-of-function mutations in ENG cause hereditary hemor-
rhagic telangiectasia type I (HHT1) (2), which is characterized
by telangiectases affecting the nose, gastrointestinal tract, and
skin, as well as larger arteriovenous malformations (AVM) in the
brain, lung, and liver. ENG mutations have also been reported in
patients with pulmonary arterial hypertension (PAH), a vascular
disorder characterized by the remodeling of small pulmonary
vessels, resulting in increased right ventricular systolic pressure
that ultimately leads to right-sided heart failure (3).
ENG has a large extracellular domain (ECD) and a short
cytoplasmic tail, and its ECD can be cleaved from the cell sur-
face under conditions related to endothelial dysfunction and
inflammation (4). Cleaved ENG ECD, also known as soluble
endoglin (sENG), is markedly elevated in preeclampsia (PE) and
contributes to the pathogenesis of PE (5). Circulating sENG is
also elevated in PAH and is proposed to be a biomarker for the
prognosis of group I PAH patients (6). Intriguingly, adminis-
tration of sENG reduces cardiac fibrosis in pressure overload-
induced heart failure in mice (7).
In preclinical studies, loss of ENG leads to increased EC
proliferation, decreased cell migration against flow, and reduced
flow-mediated EC elongation (8–10). How ENG regulates such
important cellular functions at the molecular level is not known.
ENG was originally discovered as a component of the trans-
forming growth factor-β (TGFβ) family signaling complex (11).
TGFβ family ligands, including bone morphogenetic proteins
(BMPs), are homodimers, initiating the cellular signaling by forming
a signaling complex at the plasma membrane with 2 copies of a type
I receptor and 2 copies of a type II receptor. TGFβ type I receptor
(TGFβRI), also termed Activin receptor-like kinase (ALK)5, and
TGFβ type II receptor (TGFβRII) mediate signaling from TGFβ1,
-β2 and -β3, whereas ALK1 has been reported to participate in
signaling in response to both TGFβ and BMPs (12, 13). ENG and
betaglycan are coreceptors for the TGFβ family signaling, and both
are single-pass transmembrane proteins (14). While their trans-
membrane and cytoplasmic domains show high sequence similarity
(71% similarity with 63% identity in human), the extracellular do-
mains of ENG and betaglycan share little sequence homology (11).
While the coreceptor function of betaglycan is to capture and dis-
play TGFβ2 to its receptors (15), the molecular function of ENG
is less well understood with many controversial reports and unan-
swered questions in the field. For example, using radio-labeled li-
gands and coimmunoprecipitation, ENG was initially identified
as a component of the TGFβ receptor system, binding to TGFβ1
and TGFβ3 but not TGFβ2 (11); hence, sENG was proposed as a
Significance
Endoglin (ENG) is a dimeric transmembrane accessory receptor
highly expressed on endothelial cells. Its extracellular domain
can be cleaved and released into circulation as soluble ENG
(sENG). Higher levels of sENG contribute to the pathogenesis of
preeclampsia (PE). Bone morphogenetic protein 9 (BMP9), a
circulating signaling molecule and vascular quiescence factor,
binds sENG with high affinity. Hence sENG has been thought to
be a dimeric molecule and an inhibitory ligand trap for BMP9.
Here we show that sENG purified from human tissues is mo-
nomeric and that the sENG:BMP9 complex is an active signaling
molecule, but requires cell-surface ENG for optimal signaling.
This study provides insight for understanding the role of sENG
in PE and other cardiovascular diseases.
Author contributions: A.L., Z.T., M.T., R.E.R., D.S.C.-J., H.M.A., P.t.D., and W.L. designed
research; A.L., Z.T., M.T., R.E.R., J.C., M.v.D., D.S.C.-J., and W.L. performed research; G.B.A.,
D.S.C.-J., H.M.A., P.t.D., and W.L. contributed new reagents/analytic tools; A.L., Z.T., M.T.,
R.E.R., J.C., M.v.D., N.W.M., G.B.A., D.S.C.-J., H.M.A., P.t.D., and W.L. analyzed data;
H.M.A., P.t.D., and W.L. jointly supervised the research; and N.W.M., D.S.C.-J., H.M.A.,
P.t.D., and W.L. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission.
This open access article is distributed under Creative Commons Attribution License 4.0
(CC BY).
Data deposition: The microarray data have been deposited in the Gene Expression
Omnibus (GEO) database, https://www.ncbi.nlm.nih.gov/geo (accession no. GSE119206).
1A.L., Z.T., M.T., and R.E.R. contributed equally to this work.
2To whom correspondence may be addressed. Email: wl225@cam.ac.uk.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1816661116/-/DCSupplemental.
Published online August 20, 2019.
17800–17808 | PNAS | September 3, 2019 | vol. 116 | no. 36 www.pnas.org/cgi/doi/10.1073/pnas.1816661116
D
ow
nl
oa
de
d 
at
 C
am
br
id
ge
 U
ni
ve
rs
ity
 o
n 
M
ar
ch
 6
, 2
02
0 
ligand trap for TGFβ1 (5). However, subsequent biochemical
studies using purified recombinant ENG ECD-Fc fusion protein
(ENG-Fc) revealed that ENG ECD binds directly with high af-
finity only to BMP9 and BMP10, but not to other TGFβ family
receptors or ligands; hence, sENG has been proposed to be a ligand
trap for BMP9 and BMP10 (16). Moreover, it has been shown that
TGFβ1 can signal through ALK1 and ALK5 in endothelial cells,
and its signaling through ALK1 requires ENG (12, 17, 18). How-
ever, ALK1 was later found to be a specific type I receptor for
BMP9 and BMP10 (13, 19). Third, although ENG has been shown
to inhibit TGFβ signaling (20), the requirement of ENG for
BMP9 signaling has not been unequivocally established (21, 22).
BMP9 is synthesized by the liver and circulates at active con-
centrations in a prodomain-bound form (pro-BMP9) with its pro-
domain noncovalently bound to its growth factor domain (GFD)
(23). The crystal structure of the sENG N-terminal orphan domain
in complex with BMP9-GFD demonstrates that sENG binds to
BMP9 at sites overlapping with the prodomain and the type II re-
ceptors (24–26). This implies that ENG ECD will need to displace
the prodomain from BMP9 and then dissociate from BMP9 to al-
low type II receptor binding and the formation of the signaling
complex. Using Biacore sandwich complex formation assays and
measuring the changes in response units, it has been proposed that
BMP9 prodomain can be displaced by the binding of ALK1, type
II receptors, and sENG (27), although direct evidence from solution
studies is yet to be shown. In order to assimilate the information
into a coherent model of sENG function, a number of important
questions remain unanswered, such as the physiological form of
circulating sENG and whether sENG inhibits BMP9 signaling at
physiologically relevant concentrations. The role of cell-surface
ENG versus sENG function is also unclear.
To address these questions, we performed a detailed bio-
chemical dissection of the protein–protein interactions between
ENG ECD with BMP9 and its binding partners. We provide
evidence that circulating sENG is primarily in the monomeric
form and that monomeric sENG can readily displace the pro-
domain from pro-BMP9 to form a stable complex with BMP9.
Moreover, sENG is not an inhibitory BMP9 ligand trap; instead,
the purified sENG:BMP9 complex can signal in ECs with similar
potency and specificity as pro-BMP9, but cell-surface ENG is
required for optimal sENG:BMP9 signaling.
Results
Soluble Endoglin Purified from Human Placenta and Plasma Is
Primarily Monomeric. In order to characterize sENG, we expressed
full-length ECD of human ENG containing amino acid residues 1 to
586 with a C-terminal His-tag in HEK293-EBNA cells (Fig. 1A).
Conditioned medium from transfected cells contains both dimeric
and monomeric sENG, which could be separated by gel filtration
chromatography (Fig. 1 B–D). Similar results could be obtained
using a construct without the His-tag (SI Appendix, Fig. S1 A and B),
confirming that the C-terminal His-tag does not interfere with the
dimerization. To determine whether sENG from natural sources is
in a dimeric or monomeric form, we purified sENG from condi-
tioned medium of ex vivo cultured full-term human placenta from
healthy individuals using an anti-ENG antibody affinity column.
Placenta-derived sENG is predominantly in the monomeric form,
with a mixture of full-length ECD and smaller fragments (Fig. 1E).
Similarly, sENG purified from plasma samples of PE and normo-
tensive controls is also predominantly in the monomeric form and is
slightly smaller than the full-length recombinant ECD (Fig. 1E).
This is consistent with a previous report that sENG from PE plasma
has truncations from the C terminus of the ECD (5). To exclude the
possibility that the anti-ENG antibody column preferentially binds
sENG monomers over dimers, we showed that both dimeric and
monomeric sENG bound to anti-ENG columns equally well (SI
Appendix, Fig. S2A), even in the presence of BMP9 (SI Appendix,
Fig. S2B).
Monomeric Form of sENG Is Stable under Oxidized Conditions as in PE
Plasma. Since plasma from PE patients comprises a more oxi-
dizing environment than plasma from healthy controls (28), we
next investigated which form of sENG is more stable in such an
environment. We first tested whether oxidizing reagents known
to promote disulfide bond formation (28–31) could switch sENG(M)
into sENG(D). Surprisingly, none of the oxidizing reagents pro-
moted intermolecular disulfide bond formation in sENG(M),
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Fig. 1. Generation and characterization of soluble endoglin. (A) Schematic
illustrating the domain structure of human ENG and recombinant sENG.
Cys516 and Cys582 participate in the intermolecular disulfide bond forma-
tion (24, 47). SP: signal peptide; TM: transmembrane domain; CT: cytoplasmic
tail. (B) Soluble ENG expressed in the mammalian cells contains a mixture of
dimer and monomer. Conditioned medium from HEK293-EBNA cells trans-
fected with sENG construct was fractionated on a 4 to 12% Bis-Tris non-
reducing SDS/PAGE and immunoblotted with anti-ENG antibody. (C) Fractions
from the final S200 16/60 gel filtration column of sENG purification were run on
a 12% nonreducing SDS/PAGE and stained with Coomassie Blue, showing the
separation of sENG monomer (M) from dimer (D). (D) Comparison of in-house–
purified sENG with that from R&D Systems by equal loading of purified proteins
on an SDS/PAGE in the absence or presence of reducing reagent (DTT) and
stained with Coomassie Blue. (E) Soluble ENG purified from biological sources is
primarily monomeric. Soluble ENG from different sources was run on a 10%
nonreducing SDS/PAGE and immunoblotted with anti-ENG antibody. Lane 1,
sENG from R&D Systems; lanes 2 and 3, in-house–purified recombinant sENG
dimer and monomer; lanes 4 and 5, sENG purified from conditioned media of 2
independently ex-vivo–cultured, human full-term fresh placenta from 2 healthy
individuals; lanes 6 and 7, sENG purified from pooled plasma of PE (lane 6) and
normotensive pregnant women (lane 7). Note that recombinant sENGs shown
here are all with C-terminal His-tag. Similar results were obtained for a non-
tagged recombinant sENG which are shown in SI Appendix, Fig. S1. The ap-
parent difference of the sENG sizes between Coomassie Blue-stained gel and
Western blots was due to the difference in molecular weight markers (SI
Appendix, Fig. S1C).
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whereas sENG(D) was very sensitive to the presence of oxidized
glutathione (GSSG)/reduced glutathione (GSH) redox buffer.
H2O2 caused degradation in both sENG(M) and sENG(D), with
greater effects on sENG(D) (Fig. 2A). We next incubated both
forms of sENG in GSSG/GSH buffers, spanning conditions more
oxidized than those shown by Zhou et al. (28) (Fig. 2B, red box).
Redox buffer has typically been used in the refolding of extra-
cellular proteins to promote disulfide reshuffling and formation
(30). Again, sENG(M) was very stable in all conditions tested,
whereas sENG(D) tended to convert into the monomer (Fig. 2B
and SI Appendix, Fig. S1D), suggesting that the intermolecular
disulfide bond in sENG(D) is labile.
These results led us to question whether there are free cys-
teines present in sENG(M) and sENG(D). We performed free
thiol modification using 3 complementary methods: First,
PEG5000 maleimide (mPEG5K), which modifies free cysteines
resulting in the addition of 5 kDa of molecular weight for each
modification and a band shift on SDS/PAGE (28); second, 5-
Iodoacetamido-Fluorescein (5-IAF), a sulfhydryl-reactive deriva-
tive of fluorescein that labels accessible free cysteines (32, 33) and
allows the detection of labeled protein by fluorescence (29); third,
Ellman’s reagent 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB) (34),
which reacts with the accessible free -SH group and allows quan-
tification of free thiols by the highly chromogenic compound TNB.
As shown in SI Appendix, Fig. S3, despite positive and negative
controls showing the expected thiol modification results, no dif-
ference was observed in free cysteine labeling between sENG(M)
and sENG(D) using all 3 methods. mPEG5K and 5-IAF did not
detect any accessible free cysteines, whereas DTNB, the smallest
molecule of the 3 labeling reagents, could detect one free cysteine
in both dimeric and monomeric sENG.
Both Dimeric and Monomeric sENG Form Complexes with BMP9, and
sENG Interacts with ALK1 ECD via BMP9. Since sENG binds BMP9-
GFD with high affinity (16), we next investigated how sENG
interacts with other components of BMP9 signaling complexes.
Using coexpression followed by pull-down assays, Saito et al.
have shown that ENG, BMP9, and ALK1 can form a ternary
complex and that BMP9 mediates the interaction between ENG
and ALK1 (24). We set out to investigate such interactions using
purified recombinant proteins. Using native polyacrylamide gel
electrophoresis (PAGE), we were unable to detect any direct in-
teraction between sENG and ALK1 or BMPRII ECD (Fig. 3A).
However, when sENG was premixed with BMP9 before native
PAGE, a clear band shift was observed (Fig. 3B), and an addi-
tional band shift was detected when ALK1 ECD was included in
the mixture (Fig. 3B), indicating the formation of sENG:BMP9
and sENG:BMP9:ALK1 complexes, respectively. The identities of
sENG:BMP9 and sENG:BMP9:ALK1 complexes on the native
PAGE were confirmed by subsequent SDS/PAGE analysis of
these bands excised from the native gel (Fig. 3B). To further
demonstrate that sENG interacts with ALK1 via BMP9, we car-
ried out an analytical gel filtration experiment (Fig. 3C). In the
absence of BMP9, neither dimeric nor monomeric sENG coeluted
with ALK1 ECD, whereas, in the presence of BMP9, sENG, and
ALK1, ECD coeluted with BMP9. It is interesting to note that,
upon mixing pro-BMP9 with sENG and ALK1 ECD in solu-
tion, the prodomain was displaced (Fig. 3C, lane 9 on SDS/
PAGE). The displacement of the prodomain was investigated
further (below).
We next questioned whether the sENG:BMP9 complex is
present in vivo and could be detected in plasma samples from PE
patients and normotensive controls. Since sENG from plasma is
monomeric, we investigated only sENG(M) in this study. First, we
established an ELISA specific for the sENG(M):BMP9 complex
(SI Appendix, Fig. S4). Control experiments showed that this
ELISA specifically detects the sENG(M):BMP9 complex, not
sENG(M) or pro-BMP9 on their own, whereas a BMP9 ELISA
could detect BMP9 in both the sENG(M):BMP9 complex and
pro-BMP9 equally well. Similarly, the sENG ELISA could detect
free sENG(M) and sENG(M) in complex with BMP9 equally well
(SI Appendix, Fig. S4). Plasma samples from PE patients and
controls were assayed using all 3 ELISAs. The clinical character-
istics of the controls and PE patients are summarized in SI Ap-
pendix, Table S1. There was no difference in overall circulating
BMP9 levels between PE patients and normotensive control
subjects. However, concentrations of sENG were significantly
higher in plasma from PE patients, consistent with previous
findings (5). The sENG(M):BMP9 complex was present in both
groups and slightly higher in the PE group (Fig. 3D and SI Ap-
pendix, Fig. S5).
Binding of sENG to Pro-BMP9 Displaces the Prodomain. In order for
circulating pro-BMP9 to bind ENG, the prodomain needs to
be displaced (Fig. 4A). The importance of this interaction led us
to extend our initial observation of prodomain displacement
(Fig. 3C). We first performed a pull-down experiment using
recombinant sENG (D+M) and pro-BMP9 (Fig. 4B). When pro-
BMP9 was applied to a nickel-chelating column preloaded with
His-tagged sENG, BMP9-GFD was retained on the column
whereas the prodomain was in the flow-through (Fig. 4B). We
also performed a native PAGE analysis with a follow-up SDS/
PAGE confirming the identities of each band from the native
PAGE. As shown in Fig. 4C, pro-BMP9 was separated as 3 bands
on a native PAGE, corresponding to BMP9-GFD, the pro-
BMP9 complex, and the prodomain alone. When pro-BMP9 was
preincubated with an increasing amount of sENG before being
loaded onto the native PAGE, the pro-BMP9 complex decreased
with increasing amounts of sENG, with a concomitant increase
in intensity of bands containing the sENG:BMP9 complex and
prodomain, indicating further release of the prodomain from the
pro-BMP9 complex by sENG (Fig. 4C). Finally, to confirm that
the physiological form of sENG is capable of displacing the
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Fig. 2. Monomeric sENG is stable under oxidizing environment. (A) sENG(M) is
very stable under oxidizing conditions. Equal amounts of sENG monomer (M)
or dimer (D) were incubated in either PBS or PBS with 1 mM hydrogen per-
oxide, 100 μM Diamide, 0.2 mM/2 mM GSSG/GSH, or 0.2 mM/2 mM cystine
(CSSC)/cysteine (CSH) at 25 °C for 3 h. Samples were then subjected to 12%
nonreducing SDS/PAGE and Coomassie Blue staining. The experiment was re-
peated 4 times and 1 representative gel is shown. (B) sENG(M) is very stable in
GSH/GSSG redox buffer. Red box highlights the most oxidized buffer condition
tested in Zhou et al. (28).
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prodomain, we performed gel filtration with purified sENG(M)
and pro-BMP9 and showed that sENG(M) could evict the pro-
domain in the absence of ALK1 (Fig. 4D). Altogether, these 4
independent solution-based studies provide compelling evidence
that both sENG(D) and sENG(M) are able to readily and ef-
fectively displace the prodomain from BMP9.
Soluble ENG Does Not Inhibit BMP9 Signaling at Physiological
Concentrations. Soluble ENG is often considered to be a ligand
trap for BMP9 and BMP10 based on studies using ENG-Fc fu-
sion protein (16, 35), but the effect of monomeric sENG (its
natural circulating form) has not been investigated. We therefore
performed the BMP9-mediated signaling assay in endothelial
cells in the presence of sENG monomer from 4 to 1,000 ng/mL,
which broadly spans the full range of concentrations measured in
human plasma [3 to 4 ng/mL measured in healthy individuals to
40 to 150 ng/mL in PE patients (5, 6)]. In human pulmonary
artery endothelial cells (PAECs), sENG(M), at all concentra-
tions tested, did not inhibit Smad1/5 phosphorylation (Fig. 5A)
nor ID1 gene induction (Fig. 5B) induced by BMP9-GFD or pro-
BMP9. To further determine whether sENG could act as a ligand
trap and inhibit BMP9 signaling in another cell type, we per-
formed BRE-luciferase reporter assays using C2C12 myoblast
cells transfected with human ALK1. Smad1/5-dependent BRE-
luciferase activity was potently induced by BMP9-GFD fol-
lowing ALK1 transfection, but this activity was not inhibited by
sENG(M). This confirms that sENG is not an inhibitory ligand
trap for BMP9 (Fig. 5C). Of note, using a similar concentration
range, we did not find any evidence of sENG(D) inhibiting
BMP9 signaling in PAECs (SI Appendix, Fig. S6 A and B).
However, ENG-Fc, at a concentration of 1,000 ng/mL did par-
tially inhibit pro-BMP9, but not BMP9-GFD–induced Smad1/5
phosphorylation (SI Appendix, Fig. S6C).
Since sENG can form a stable complex with BMP9 in solution,
and sENG is not a ligand trap for BMP9, we went on to compare
the signaling activity of the sENG(M):BMP9 complex with the
circulating form of pro-BMP9. Two preparations of sENG(M):BMP9
complexes were generated using different protocols (SI Appendix,
Fig. S7). BMP9-GFD concentrations in each protein preparation
were quantified by BMP9 ELISA, and signaling assays were per-
formed using molar equivalent concentrations of BMP9-GFD. No
difference in signaling potency in human PAECs was found be-
tween sENG(M):BMP9 and pro-BMP9 (Fig. 5 D and E). Similar
results were obtained for sENG(D):BMP9 (SI Appendix, Fig.
S6D). We next asked whether sENG(M):BMP9 has signaling ca-
pacity at the range of (patho)physiological concentrations of
sENG (5 to 100 ng/mL). As shown in Fig. 5F, sENG alone did not
initiate Smad1/5 phosphorylation, whereas both sENG(M):BMP9
and sENG(M):BMP10 (generated in parallel with sENG:BMP9,
SI Appendix, Fig. S7B) displayed potent signaling activity in the
pathophysiological range of sENG concentrations.
In order to directly compare the downstream target genes
regulated by the sENG(M):BMP9 complex and pro-BMP9, we
profiled the hPAEC transcriptome induced by these 2 ligands
using a microarray (36). For both treatments, we used the equiv-
alent concentration of 0.4 ng/mL BMP9-GFD as a representative
physiological concentration of BMP9 in healthy controls (37). The
primary target genes were measured after 1.5 h of treatment.
Comparison of pro-BMP9 or sENG(M):BMP9 with vehicle con-
trol (PBS) gave rise to a similar set of up- and down-regulated
genes (Fig. 5 G and H), and no difference was detected when
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Fig. 3. Soluble ENG binds BMP9 directly and interacts with ALK1 via BMP9.
(A) No complex formation could be detected by native PAGE between sENG
with either ALK1 or BMPRII ECDs. Samples in each lane were premixed as
indicated and incubated at room temperature for 10 min before being
loaded onto a 10% native PAGE. Two parts of the same gel are shown. The
colored circles are used to label different proteins, with a single circle in-
dicating a monomer and twin circles indicating the dimer. The key to the
colored circles is shown below. (B) Complex formation analysis by native
PAGE. (Left) Samples in each lane were premixed as indicated and incubated
at room temperature for 10 min before being loaded onto a 10% native
PAGE. Both dimer and monomer sENG can form complexes with BMP9,
showing as band-shifts compared with sENG alone. The sENG:BMP9 complex
can form a further complex with ALK1 ECD, showing as an additional band-
shift. (Right) Bands 1 to 5 on the native PAGE were excised and rerun on a
12% nonreducing SDS/PAGE to confirm the protein components in each
band. The band labeled with an asterisk (*) was not characterized in this
experiment, but could be the complex between BMP9 and ALK1 ECD as
observed previously (51). (C ) sENG interacts with ALK1 ECD via BMP9.
Purified sENG (a mixture of dimer and monomer), ALK1 ECD, and pro-
BMP9 were run on a S75 10/30 gel filtration column, pre-equilibrated in
buffer containing 50 mM Tris. HCl, pH 7.4, 150 mM NaCl, either by itself or
in combination, as indicated. Eluted fractions from each run were col-
lected and traces were overlaid (Left). Gel filtration standards were run,
and the peak positions of each standard are shown above. Fractions were
collected in each run, and at positions indicated as 1 to 11, fractions were
precipitated by Trichloroacetic acid and run on a 12% nonreducing SDS/
PAGE (Right). Identities of the proteins on the SDS/PAGE are labeled using
colored circles as in A. A cartoon diagram, using the same color scheme as
the circles, illustrates complex formation and the displacement of BMP9-
prodomain. In the sENG:BMP9:ALK1 complex, sENG could be either
monomer or dimer. (D) sENG:BMP9 complex can be detected in PE plasma.
Plasma samples from 18 PE patients and 11 normotensive controls were subject
to ELISA measurements for sENG, BMP9, and the sENG:BMP9 complex. De-
tailed methods and antibody pairs used in the ELISA measurements are de-
scribed in SI Appendix,Materials and Methods. All measurements were carried
out blind to the patient groups. For sENG:BMP9 measurements, one data
point was excluded, and the complete dataset and the criteria for the ex-
clusion are discussed in SI Appendix, Fig. S5. Means ± SEM are shown, and
data were analyzed by 2-tailed unpaired t-test, ****P ≤ 0.0001; ns, not
significant.
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comparing genes regulated by pro-BMP9 versus sENG(M):BMP9
(Fig. 5I), again confirming that sENG did not interfere with BMP9
signaling and supporting the conclusion that sENG(M):BMP9 has
similar signaling capacity to pro-BMP9 in endothelial cells. There
were 94 transcripts significantly regulated by pro-BMP9 treatment
and 61 by sENG(M):BMP9; these are listed in Datasets S1 and S2,
respectively. There was almost complete overlap in the transcripts
regulated by these 2 treatments (49, P = 1.3 × 10−106), and the
magnitude of the transcript fold change elicited was highly cor-
related (R2 = 0.991, Dataset S3). This list of transcripts also
overlaps with the 19 BMP9 target genes recently identified by
Araki et al. (38).
Coreceptor Function of the Cell-Surface ENG. In the final set of ex-
periments, we asked whether the protein–protein interactions
observed for sENG in solution could provide insights into the
function of cell-surface ENG. First, we sought to confirm the
presence of the ENG:BMP9:ALK1 complex on the endothelial
cell surface. PAECs were cross-linked with 125I-BMP9, followed
by immunoprecipitation (IP) using antibodies against several
cell-surface receptors in turn. Common bands can be detected in
anti-ALK1 and anti-ENG IPs which were not present in IP using
the control antibodies anti-ActRIIb or anti-Flag (Fig. 6A), pro-
viding evidence for the presence of the ternary complex of
ENG:BMP9:ALK1. Interestingly, strong bands were detected in
anti–BMPRII-IP samples, suggesting that cell-surface BMPRII
binds 125I-BMP9.
Next, we investigated the impact of cell-surface ENG expres-
sion on sENG function. Pulmonary endothelial cells from Eng
floxed mice (Rosa26-CreERT2;Engfl/fl) were prepared as in pre-
vious studies (39, 40), and Eng was depleted from endothelial
cells in culture by transient treatment with 4-hydroxy-tamoxifen
allowing the direct comparison of BMP9 signaling in control and
Eng depleted (Eng-iKO) endothelial cells. Immunofluorescent
staining confirmed that Eng-iKO endothelial cells were com-
pletely lacking ENG but still maintained endothelial CD31
expression indistinguishable from control cells (Fig. 6B). In-
cubating ECs with biotin-labeled BMP9-GFD followed by flow
cytometric quantification of cell-surface bound biotin showed al-
most 50% reduction in BMP9 binding to cell surface in Eng-iKO
ECs (Fig. 6C), consistent with a role for membrane ENG in pro-
viding a local supply of BMP9 ligand available to enhance signaling.
In fact, Eng-iKO cells had almost 40% reduced pSmad1/5 signaling
responses to both BMP9-GFD and pro-BMP9 (Fig. 6D). Interest-
ingly, when sENG(M):BMP9 and sENG(D):BMP9 complexes were
used as the source of BMP9 ligand, the response of Eng-iKO cells
was even further depressed compared with control cells (Fig. 6D),
suggesting that membrane ENG may be important in releasing
BMP9 from the sENG:BMP9 complexes in order to initiate sig-
naling. As serum is an important source of BMP9 in vivo, we also
examined the effect of serum on signaling responses in Eng-iKO
cells. In the presence of serum alone there is a small but consistent
reduction in pSmad1/5/8 signaling in Eng-iKO compared with
control ECs (Fig. 6E). With increasing concentrations of sENG(D)
this effect escalates considerably such that pSMAD1/5 activation
in response to serum in the presence of 100 ng/mL sENG(D) is
reduced by ∼70% in the absence of membrane ENG, indicating
that membrane endoglin is critical for making serum pro-BMP9
available for signaling in the presence of pathophysiological sENG
concentrations. The role of cell-surface ENG in BMP9 signaling
was further confirmed by the observation that an ENG antibody
that blocks BMP9 binding to ENG (21) can inhibit BMP9-induced
Smad1/5 phosphorylation (Fig. 6F).
Discussion
In this report, we characterized recombinant sENG expressed
from mammalian cells as well as that from ex vivo cultured
placenta conditioned media and human normotensive and PE
plasma samples. We found that, contrary to previous expecta-
tions, the circulating form of sENG is monomeric, even in PE
patients, instead of the widely assumed S-S–linked dimer.
We also demonstrated here that, at physiological concentra-
tions, sENG does not act as an inhibitory ligand trap for BMP9
and that the sENG(M):BMP9 complex can initiate Smad1/5-
dependent signaling in human primary endothelial cells which is
indistinguishable from that of the circulating form of pro-BMP9.
Indeed, sENG treatment can reduce the incidence of AVMs in a
mouse model of HHT1 (41), suggesting that it may enhance
BMP9/10 signaling in vivo in the absence of endogenous ENG.
However, we show here that the sENG:BMP9 complex requires
membrane ENG for the most efficient signaling. It is also worth
noting here that, in the setting of therapeutic intervention to
target angiogenesis using ENG-Fc, which is an artificially dimeric
form of sENG, it is possible for ENG-Fc to function as a ligand
trap for BMP9 and BMP10.
We show here that monomeric sENG is very stable in a mul-
tiple oxidizing environment. From the crystal structures of ENG
orphan domain and the ZP domain, only 4 cysteines, Cys242,
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sENG:BMP9 complex. (B) Prodomain displacement assay on a Ni-NTA column.
Details are described in SI Appendix, Materials and Methods. Selected sam-
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Fig. 5. Soluble ENG does not inhibit BMP9 signaling at physiological concentrations. (A and B) sENG(M) does not inhibit BMP9 signaling in hPAECs. Serum-
starved hPAECs were treated with BMP9-GFD or pro-BMP9, both of which had been preincubated with sENG(M) at indicated concentrations. Cells were
harvested after either 15 min for pSmad1/5 immunoblotting analysis (A) or 1 h for RT-qPCR analysis (B). n = 3 for both immunoblot and qPCR analysis.
Means ± SEM are shown in B. (C) sENG does not inhibit BMP9 signaling in C2C12 cells. Transfection of ALK1-sensitized C2C12 cells’ response to BMP9 at
concentrations below 1,000 pg/mL. This ALK1-mediated BMP9 signaling, measured by a BMP-responsive element driven luciferase transcriptional reporter
expression, was not inhibited by sENG(M) at 16 ng/mL. Means ± SEM are shown. (D) Purified sENG(M):BMP9 complex has similar potency to pro-BMP9 in
inducing Smad1/5 phosphorylation. Serum-starved hPAECs were treated with pro-BMP9 alone or with 2 independent preparations of the
sENG(M):BMP9 complex (SI Appendix, Fig. S7). After 15 min of treatment, cell lysates were harvested and subjected to immunoblotting analysis. Anti–
α-tubulin was used as a loading control. (E) Purified sENG(M):BMP9 complex has similar activity to pro-BMP9 in inducing ID1 gene expression. Five lines of
hPAECs were serum-starved and treated with pro-BMP9 or sENG(M):BMP9 complex, all at 0.4 ng/mL BMP9-GFD concentrations, for 1.5 h. Cells were harvested
and ID1 gene expression was measured using RT-qPCR. Means ± SEM are shown, and data were analyzed by one-way ANOVA, Tukey’s posttest, *P < 0.05; ns,
not significant. (F) At physiological concentrations of sENG, its complexes with BMP9 or BMP10 are active in inducing Smad1/5 phosphorylation. Serum-
starved hPAECs were treated with sENG(M) alone, sENG(M):BMP9 complex (prep2), or sENG(M):BMP10 complex (SI Appendix, Fig. S7). After 15 min of
treatment, cells were harvested and analyzed as above. All sENG concentrations were quantified using an SDS/PAGE and Coomassie Blue staining, using sENG
from R&D Systems as standard. (G–I) sENG(M):BMP9 complex regulates the same set of target genes as pro-BMP9 in hPAECs. Serum-starved hPAECs were
treated with PBS, pro-BMP9, or sENG(M):BMP9 at concentrations equivalent to 0.4 ng/mL BMP9-GFD. After 1.5 h, cells were harvested, and RNA was extracted
for microarray analysis. Volcano plots showing the differential gene expression, with hits above the dotted line having the adjusted P value of less than 0.05.
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Fig. 6. Coreceptor function of the cell surface ENG. (A) ALK1:BMP9:ENG complex can be detected on endothelial cell surface. Near confluent PAECs were
incubated with 125I-BMP9 followed by chemical cross-linking and IP with antibodies indicated above the lanes. Two parts of the same gel are shown. Arrows
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positive CD31 staining with (control) and without (Eng-iKO) membrane ENG (Scale bar, 50 μm.) (C) Flow cytometry analysis shows that biotinylated recombinant
human BMP9 (rhBMP9) binds with reduced efficiency to Eng-iKO endothelial cells compared with control. (D) Eng-iKO endothelial cells have reduced Smad1/5-
dependent BMP9 signaling in response to recombinant BMP9 and pro-BMP9 compared with controls. This signaling is further reduced in Eng-iKO endothelial cells
when BMP9 ligand is presented in complex with sENG(M) or sENG(D). (E) sENG inhibits serum-induced Smad1/5 phosphorylation more profoundly in Eng-iKO
MLECs than in controls. For D and E, quantification of band intensities, means ± SEM are shown; one-way ANOVA, Tukey’s posttest was used for analysis. *P <
0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001. (F) Anti-ENG antibody TRC105 inhibits BMP9 signaling. TRC105 (10 μg/mL) or control IgG was preincubated with
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Two parts of the same gel are shown. Densitometric quantification from the blots (30 min treatment, n = 3) is shown on the right.
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Cys330 (not resolved in the structure), Cys516, and Cys582, in
ENG ECD were not seen in the intramolecular disulfide bond
form (24). It has been shown that a variant of ENG orphan do-
main lacking Cys242 and Cys330 is secreted as efficiently as wild
type and retains BMP9-binding activity (24). Interestingly, a
mammalian maltose-binding protein-fused ENG ZP domain,
containing Cys516 and Cys582, was also expressed as a mixture of
monomer and dimer, and crystallization selected the monomer
form (24).
Role of Monomeric sENG in the Onset of PE and Other Cardiovascular
Diseases. Our results shed light on 2 important questions re-
garding sENG: 1) How should results from studies using non-
physiological forms and concentrations of sENG be interpreted?
2) Is there a pathogenic role for sENG in PE and other cardio-
vascular diseases?
First, the in vivo form and concentrations of sENG need to be
considered when investigating the role of sENG. Many studies
have used high concentrations of sENG to study its pathophys-
iological effects, such as adenoviral-expressed sENG (5), trans-
genic overexpression of a truncated form of sENG (42–44), or
ENG-Fc administration (5). Soluble ENG in such in vivo studies
may not resemble the forms nor the concentrations found in
humans and may not cause pathological effects through the
same mechanism.
The pathogenic role of sENG in PE was initially thought to be
because of its role as a ligand trap for TGFβ (5). Subsequent data
showing the lack of direct binding of sENG to TGFβ have
changed the view to sENG being the ligand trap for the high-
affinity ligands BMP9 and BMP10 (16). Our data showing that
sENG:BMP9 signals in hPAECs with similar potency to circu-
lating pro-BMP9 refutes this. In addition, our data do not sup-
port the view that increased sENG alone is causal for endothelial
dysfunction, which is in agreement with a recent report (45).
Although the levels of sENG have been suggested as a biomarker
of cardiovascular disease progression and treatment (6, 46), it is
possible that changes in sENG levels are the consequences of the
changes in the protein levels of cell-surface ENG which may also
play a role in the disease pathogenesis. It has been shown that
when sENG is elevated in circulation, increased cell-surface
ENG is also detected (5, 7). Our data suggest that a small in-
crease in circulating sENG concentrations in some patient
groups, such as changes from ∼4 ng/mL in healthy controls to
∼8 ng/mL as measured in PAH patients (6), more likely reflects
the consequence of endothelial dysfunction and increased
shedding of cell-surface receptors, rather than sENG directly
contributing to the disease pathogenesis.
Coreceptor Function of ENG. BMP9 and BMP10 are unique among
the BMP family members in that they do not have the N-terminal
heparin-binding region, and there is no known motif in BMP9 or
BMP10 prodomains to suggest that they interact with an extra-
cellular matrix. Therefore, one potential role of cell-surface
ENG is to capture and present circulating BMP9 and BMP10,
thereby increasing their local concentrations on the endothelial
cell surface. This would be analogous to that of extracellular
matrix and heparin for other BMPs (14), Indeed, we show that
Eng-iKO endothelial cells have reduced capacity to bind
BMP9 and compromised BMP9 signaling. The binding of sENG
to form the sENG:BMP9 complex does not inhibit BMP9-
initiated cellular signals, which could be due to either cells
having intrinsic mechanisms to displace sENG to allow type II
receptor binding and the formation of the canonical signaling
complex or the type II receptors being able to directly form a
complex with the ENG:BMP9 complex. The requirement of cell-
surface ENG for mediating sENG:BMP9 signaling suggests that
transmembrane ENG, but not type II receptors, can effectively
displace sENG from the sENG:BMP9 complex.
Our data would support the following model for role of sENG
in BMP9 signaling (Fig. 7). In the Eng +/+ cells, circulating pro-
BMP9 can be captured effectively by cell-surface ALK1 and ENG.
While ALK1 can form a complex with pro-BMP9, the binding of
ENG readily displaces the prodomain (Fig. 7A). When sENG is
increased in circulation and forms an sENG:BMP9 complex (Fig.
7B), this complex can be captured by either cell-surface ENG or
ALK1 in Eng +/+ cells in a manner similar to that of pro-BMP9.
Whereas in Eng −/− cells, although sENG:BMP9 can still be cap-
tured by cell-surface ALK1, the equilibrium is disrupted and
Smad1/5 phosphorylation is reduced.
Since cell-surface ENG interacts with both BMP and TGFβ
pathways (20, 47), it could potentially act as a stoichiometric link
between the 2 pathways. The balance of endothelial BMP and
TGFβ pathways has been shown to be essential in many car-
diovascular diseases. For example, in PAH where BMP signaling
is compromised in endothelial cells, TGFβ signaling is enhanced
and inhibition of TGFβ signaling has been shown to offer ther-
apeutic benefit in preclinical PAH models (48, 49). Interestingly,
BMP9 increases endothelial cell ENG mRNA and protein ex-
pression (22), and ENG antagonizes TGFβ1 function in endothelial
cells, indicating that ENG mediates the cross-talk between BMP
and TGFβ signaling on endothelial cells. A more comprehensive
knowledge of ENG and sENG interaction network is necessary
before proper signaling assays can be designed to test these hy-
potheses. Furthermore, recent findings showing that sENG can also
be found in the circulating microsomes (50) means that sENG may
occur in additional membrane protein complexes, potentially add-
ing further complexity to this network. Undoubtedly, because ENG
is involved in many cardiovascular diseases and pathological an-
giogenesis, understanding the ENG interaction network and the
ability to manipulate such protein–protein interactions will greatly
facilitate the design of better therapeutic strategies targeting ENG
in vascular diseases and cancer.
A
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Fig. 7. Model of sENG function in BMP9 signaling at the cell surface. (A) For
pro-BMP9 signaling, high levels of ENG and ALK1 on endothelial cell surface
capture the circulating pro-BMP9 effectively in Eng +/+ cells, and the prodomain
is displaced upon ENG binding. ENG and ALK1 can bind BMP9 simultaneously;
therefore, the ternary complex of ENG:BMP9:ALK1 can be formed at the cell
surface. In Eng −/− cells, pro-BMP9 can be captured only by cell-surface ALK1;
therefore, less efficient capturing results in slightly reduced signaling. (B)
sENG(M):BMP9 complex can initiate normal signaling in Eng +/+ cells compa-
rable to pro-BMP9, but not in Eng −/− cells, suggesting that cell-surface ENG is
required for the signaling, presumably by displacing the sENG from the com-
plex. Note that the stoichiometry of ENG and ALK1 is not depicted here, nor is
the role of type II receptors.
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Materials and Methods
Human Samples. The normal placental tissue collection was approved by the
Cambridgeshire 2 Research Ethics Committee (reference number 07/H0308/
163), and all participants provided written informed consent. Clinical data
and blood samples were obtained from participants in the Preeclampsia and
Non-Preeclampsia Database (PANDA) program of the Department of
Obstetrics & Gynecology of the Academic Medical Center in Amsterdam,
The Netherlands. Normotensive pregnant women and preeclamptic
women with and without HELLP syndrome participating in the PANDA an-
tenatal program were recruited consecutively. Experiments were carried out
in accordance with the declaration of Helsinki after informed written con-
sent from the participants was obtained and after experiments were ap-
proved by the ethics committee of the Academic Medical Center Hospital of
the University of Amsterdam (AMC 2010_127).
Detailed materials and methods can be found in SI Appendix. Datasets
reported here have been deposited in the GEO repository with the accession
number GSE119206.
Statistics. All qPCR, transcriptional reporter, and Western blot experiments
have been repeated at least 3 times, and representative experiments are
shown. The statistical analyses were performed using a 2‐tailed, unpaired t‐
test, or one-way ANOVA, as indicated in the figure legends. P < 0.05 was
considered statistically significant.
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